← All diseases Cancer

Lung cancer (non-small cell)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the toughest evidence (186)Meta-analysis (67)Treatment guideline (1)Randomized trial (51)Systematic review (38)Phase 3 study (29)Clinical Research (661)Review article (246)Early Study (Phase 1 or 2) (77)Case report (126)Laboratory or animal research (69)Commentary or Editorial (87)Retracted publication (14) Only studies that are currently seeking participants (78)

Filter

Publications and studies (3237)

• Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis. (2025/01/01) ♡
• Unraveling the Core Components and Critical Targets of Houttuynia cordata Thunb. in Treating Non-small Cell Lung Cancer through Network Pharmacology and Multi-omics Analysis. (2025/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recent trends and therapeutic potential of phytoceutical-based nanoparticle delivery systems in mitigating non-small cell lung cancer. (2025/01/01) ♡
• Synergistic Effect of HAD-B1 and Osimertinib Against Gefitinib Resistant HCC827 Non-Small Cell Lung Cancer Cells. (2025/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Efficacy of Chinese Medicine on Postoperative Rehabilitation of Non-small Cell Lung Cancer (NSCLC), a Randomized Controlled Study. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial. (2025/01/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy of Herbal Medicine Therapy Combined With Palliative Chemotherapy in Unresectable Advanced NSCLC: A Systematic Review and Meta-Analysis. (2025/01/01) ♡
• A prognostic nomogram of non-small cell lung cancer based on tumor marker inflammatory nutrition score. (2024/12/31) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful Diagnosis of a SMARCA4-Deficient Undifferentiated Tumor via Endobronchial Ultrasound-Guided Fine Needle Aspiration and Endobronchial Biopsies. (2024/12/30) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Association of prognostic nutritional index with long-term survival in lung cancer receiving immune checkpoint inhibitors: A meta-analysis. (2024/12/27) ♡
• Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50. (2024/12/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report. (2024/12/23) ♡
• Expression and clinical significance of programmed death ligand-1 evaluated by 22C3 antibody in pleural effusion metastatic non-small-cell lung cancer. (2024/12/20) ♡
• [Effects of Electromagnetic Pulses on Exosomes Secretion by A549 Cells]. (2024/12/20) ♡
• [Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study]. (2024/12/20) ♡
• [TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer]. (2024/12/20) ♡
• [Predictive Value of A miRNA Signature for Distant Metastasis in Lung Cancer]. (2024/12/20) ♡
• [Predictive Value of Prognostic Nutritional Index in Prognosis and Spontaneous Pleurodesis of Patients with Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion]. (2024/12/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report]. (2024/12/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The challenges and opportunities of applying tumour mutational burden analysis to precision cancer medicine. (2024/12/20) ♡
• Young lung cancer patients undergoing surgery: Comparison of clinicopathological characteristics and outcomes in patients aged ≤50 years versus >50 years. (2024/12/20) ♡
• Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY. (2024/12/18) ♡
• Flavonol-Ruthenium Complexes as Antioxidant and Anticancer Agents. (2024/12/16) ♡
• Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways. (2024/12/16) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Stereotactic Body Radiotherapy in a Transplanted Lung for a Primary Lung Cancer: Case Report. (2024/12/16) ♡
• Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC. (2024/12/16) ♡
• Indoleamine 2,3-dioxygenase 1-mediated immune suppressive status is positively associated with brain metastasis in patients with non-small cell lung cancer. (2024/12/15) ♡
• Six-year performance of risk-based selection for lung cancer screening in the Manchester Lung Health Check cohort. (2024/12/10) ♡
• Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. (2024/12/06) ♡
• Combining Robotic Navigational Bronchoscopy and Lung Resection Into a Single Anesthetic Event: Cost-Effectiveness, Wait Times, and Outcomes. (2024/12/05) ♡
• The impact of extent of nodal involvement on stage IIIA (N2) non-small cell lung cancer outcomes. (2024/12/04) ♡
• Corrigendum: Bruceine H mediates EGFR-TKI drug persistence in NSCLC by Notch3-dependent β-catenin activating FOXO3a signaling. (2024/12/03) ♡
• Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development. (2024/12/03) ♡
• Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway. (2024/12/01) ♡
• Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis. (2024/12/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Clinical research progress of fruquintinib in the treatment of malignant tumors. (2024/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study. (2024/12/01) ♡
• Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy. (2024/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study. (2024/12/01) ♡
• [Correction: Improving the nutritional situation of patients with advanced non-small cell lung cancer (NSCLC) through off-label medication]. (2024/12/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. (2024/12/01) ♡
• Clinical impact of preoperative sarcopenia and immunonutritional impairment on postoperative outcomes in non-small cell lung cancer surgery. (2024/12/01) ♡
• Phosphorylase kinase regulatory subunit alpha 1 as a novel biomarker involved in development and progression of lung cancer: comprehensive bioinformatic analysis and experiment validation. (2024/12/01) ♡
• The preoperative hemoglobin, albumin, lymphocyte, and platelet score (HALP) as a prognostic indicator in patients with non-small cell lung cancer. (2024/11/28) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors. (2024/11/26) ♡
• Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis. (2024/11/25) ♡
• Pulmonary artery enlargement as a predictor of long-term prognosis in patients with resected early-stage non-small cell lung cancer. (2024/11/23) ♡
• Should Radiation Dose Be Personalized in Patients With Localized NSCLC and Actionable Genetic Alterations? Insight From a Multicenter Real-World Study. (2024/11/22) ♡
• Three-dimensional virtual lung reconstruction in robotic segmentectomy: A safety and feasibility trial. (2024/11/20) ♡
• Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line. (2024/11/19) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.